scholarly journals Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications

2018 ◽  
Vol 84 (5) ◽  
pp. 961-971 ◽  
Author(s):  
Fiona Marra ◽  
Christoph Höner zu Siederdissen ◽  
Saye Khoo ◽  
David Back ◽  
Michael Schlag ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Clinical Impact ◽  
Pharmacokinetic Interactions ◽  
Hcv Protease ◽  
Concomitant Medications

463 PHARMACOKINETIC INTERACTIONS BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND SIROLIMUS IN HEALTHY SUBJECTS

2013 ◽  
Vol 58 ◽  
pp. S190 ◽  
Author(s):  
E.G. Hulskotte ◽  
H.-P. Feng ◽  
F. Xuan ◽  
W. Lin ◽  
Y. Zhu ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Healthy Subjects ◽  
Pharmacokinetic Interactions ◽  
Hcv Protease

Discovery and Development of the HCV Protease Inhibitor TMC435

2011 ◽  
pp. 273-286
Author(s):  
Pierre Raboisson ◽  
Gregory Fanning ◽  
Herman de Kock ◽  
Åsa Rosenquist ◽  
René Verloes ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Hcv Protease

87 MOLECULAR CHARACTERIZATION OF HCV RESISTANCE TO TELAPREVIR, A NOVEL, POTENT HCV PROTEASE INHIBITOR

2009 ◽  
Vol 50 ◽  
pp. S36
Author(s):  
S. Chevaliez ◽  
A. Ahmed-Belkacem ◽  
L. Barbotte ◽  
A. Soulier ◽  
D. Bartels ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Molecular Characterization ◽  
Hcv Protease

scholarly journals Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole

2013 ◽  
Vol 68 (6) ◽  
pp. 1415-1422 ◽  
Author(s):  
C. T. M. M. de Kanter ◽  
A. P. H. Colbers ◽  
M. I. Blonk ◽  
C. P. W. G. M. Verweij-van Wissen ◽  
B. J. J. W. Schouwenberg ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Proton Pump Inhibitor ◽  
Protease Inhibitor ◽  
Healthy Volunteers ◽  
Proton Pump ◽  
Hcv Protease ◽  
Drug Drug Interaction ◽  
Clinically Significant
Sign in / Sign up

Export Citation Format

Share Document